Manufacturing, Combination Drugs

CPHI Milan 2024: New Developments in ADC Technologies

October 10, 2024

Nicolas Camper, senior director—Bioconjugation Chemistry, Abzena, discussed new advancements in ADC technologies, including the role of complex chemistries.

AstraZeneca Plans $1.5 Billion ADCs Facility in Singapore

May 20, 2024

The new facility will be the company’s first to offer full manufacturing processing for antibody drug conjugates.

Bristol Myers Squibb and SystImmune Enter Global ADC Collaboration Worth Potentially up to $8.4 Billion

December 19, 2023

Bristol Myers Squibb and SystImmune plan to co-develop and co-commercialize lead ADC candidate for cancer treatment in US.

Distinguishing E&L Testing for Combination Products (AAPS PharmSci 360)

November 06, 2023

Dujuan Lu, PhD, global leader—E&L, SGS Health Sciences, talks about the differences in designing E&L testing for combination products vs. conventional pharmaceuticals.

Key E&L Issues to Consider During Formulation (AAPS PharmSci 360)

November 03, 2023

Dujuan Lu, PhD, global leader—E&L, SGS Health Sciences, recommends some key issues that pharma manufacturers should consider when formulating products that require a medical device.

Genentech Forms Collaboration with PeptiDream for Peptide-Radioisotope Drug Conjugates

September 26, 2023

Under a new pact, Genentech and PeptiDream will collaborate to discover and develop novel peptide-radioisotope drug conjugates.

Olon Makes Headway into ADCs Market with New Manufacturing Facility in Italy

May 31, 2023

API supplier Olon has started construction of a new manufacturing facility in Milan, Italy, which will be dedicated to production of cytotoxic payloads and linkers for ADCs.

ImmunoGen Partners with Oxford BioTherapeutics to Develop Novel ADCs

June 27, 2022

ImmunoGen has formed a research collaboration with Oxford BioTherapeutics to develop novel antibody-drug conjugates for cancers with high unmet needs.

Converting Injectable Therapies to Combination Drug-Device Products

May 15, 2022

The author describes how to seize market opportunities while navigating the requirements of both drug therapies and delivery devices.

Owen Mumford and Stevanato Group Collaborate on Auto-Injector

May 04, 2022

The two companies signed an exclusive collaboration agreement for the Aidaptus auto-injector.